Interleukin gene and its association with survival in Stage IV Lung Cancer
Not Applicable
- Conditions
- Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2023/10/058696
- Lead Sponsor
- Institute of Medical sciences and SUM Hospital SOA University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients age = 18 yrs.
2. Histopathology/cytology-proven NSCLC
3. Stage IV disease measured by CECT/PET CT
4. Adequate organ function.
Exclusion Criteria
1. Consent refusal
2. Patients already on chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association of Interleukin Gene (IL) Expression <br/ ><br>and Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer <br/ ><br>Timepoint: Baseline, 12 weeks, 24 weeks, 36 weeks
- Secondary Outcome Measures
Name Time Method Association of inflammatory genes with PD-L1 <br/ ><br>(Programmed Death Ligand ) & Desmocollin 3 Gene Expression in Stage IV Non-Small Cell Lung Cancer <br/ ><br>Timepoint: Baseline